Gilead Sciences, Inc. (GILD) Expected to Announce Earnings of $1.52 Per Share

Brokerages predict that Gilead Sciences, Inc. (NASDAQ:GILD) will announce earnings of $1.52 per share for the current quarter, Zacks reports. Seven analysts have issued estimates for Gilead Sciences’ earnings. The lowest EPS estimate is $1.44 and the highest is $1.60. Gilead Sciences posted earnings per share of $2.56 in the same quarter last year, which would indicate a negative year-over-year growth rate of 40.6%. The company is scheduled to report its next quarterly earnings results on Wednesday, July 25th.

On average, analysts expect that Gilead Sciences will report full-year earnings of $6.10 per share for the current year, with EPS estimates ranging from $5.85 to $6.38. For the next fiscal year, analysts forecast that the business will report earnings of $6.34 per share, with EPS estimates ranging from $5.75 to $7.27. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.67 by ($0.19). The business had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $5.40 billion. Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The business’s revenue was down 21.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.23 EPS.



A number of analysts recently weighed in on the stock. Royal Bank of Canada reissued a “buy” rating and issued a $94.00 target price on shares of Gilead Sciences in a research note on Friday, February 23rd. Leerink Swann reissued a “market perform” rating and issued a $80.00 target price (down previously from $83.00) on shares of Gilead Sciences in a research note on Thursday, February 22nd. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Barclays reissued an “overweight” rating and issued a $95.00 target price (up previously from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. Finally, BidaskClub cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and an average target price of $88.00.

In other news, Director John Francis Cogan sold 5,833 shares of the stock in a transaction that occurred on Friday, April 6th. The shares were sold at an average price of $74.47, for a total transaction of $434,383.51. Following the sale, the director now directly owns 58,452 shares of the company’s stock, valued at $4,352,920.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John C. Martin sold 50,000 shares of the stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $73.14, for a total transaction of $3,657,000.00. Following the sale, the director now directly owns 3,067,762 shares in the company, valued at $224,376,112.68. The disclosure for this sale can be found here. Insiders have sold 179,168 shares of company stock worth $12,789,233 over the last three months. 1.30% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Archford Capital Strategies LLC bought a new stake in shares of Gilead Sciences during the first quarter valued at approximately $106,000. Advisors Preferred LLC acquired a new position in Gilead Sciences in the first quarter valued at approximately $140,000. Stelac Advisory Services LLC acquired a new position in Gilead Sciences in the first quarter valued at approximately $141,000. Certified Advisory Corp acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $133,000. Finally, Mckinley Capital Management LLC Delaware lifted its holdings in Gilead Sciences by 67.7% in the first quarter. Mckinley Capital Management LLC Delaware now owns 2,130 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 860 shares during the period. 77.60% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences opened at $71.51 on Tuesday, according to Marketbeat Ratings. The stock has a market capitalization of $92.92 billion, a P/E ratio of 8.35, a price-to-earnings-growth ratio of -6.21 and a beta of 1.15. Gilead Sciences has a twelve month low of $64.27 and a twelve month high of $89.54. The company has a current ratio of 2.84, a quick ratio of 2.75 and a debt-to-equity ratio of 1.32.

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 28th. Stockholders of record on Friday, June 15th will be paid a dividend of $0.57 per share. The ex-dividend date is Thursday, June 14th. This represents a $2.28 annualized dividend and a dividend yield of 3.19%. Gilead Sciences’s dividend payout ratio (DPR) is currently 26.64%.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply